Tricida operates in the healthcare industry focusing on pharmaceutical business.
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 19, 2022 | Post-IPO Debt | $125M | 1 | Hercules Capital | — | Detail |
Mar 2, 2018 | Debt Financing | $100M | 1 | Hercules Capital | — | Detail |
Nov 8, 2017 | Series D | $57.50M | 1 | — | — | Detail |
Jul 25, 2016 | Series C | $55M | 1 | — | — | Detail |
Mar 4, 2015 | Series B | $30M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |
Limulus Venture Partners | — | Series D |